Related Experiment Video
Updated: Jan 23, 2026

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
Published on: June 9, 2020
Pradimicin-IRD exhibits antineoplastic effects by inducing DNA damage in colon cancer cells
Larissa Costa de Almeida1, Anelize Bauermeister2, Paula Rezende-Teixeira1
1Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Abstract:
DNA-damaging agents are widely used in cancer therapy; however, their use is limited by dose-related toxicities, as well as the development of drug resistance. Drug discovery is essential to overcome these limitations and offer novel therapeutic options. In a previous study by our research group, pradimicin-IRD-a new polycyclic antibiotic produced by the actinobacteria Amycolatopsis sp.-displayed antimicrobial and potential anticancer activities. In the present study, cytotoxic activity was further confirmed in a panel of five colon cancer, including those with mutation in TP53 and KRAS, the most common ones observed in cancer colon patients. While all tested colon cancer cells were sensitive to pradimicin-IRD treatment with IC50 in micromolar range, non-tumor fibroblasts were significantly less sensitive (p < 0.05). The cellular and molecular mechanism of action of pradimicin-IRD was then investigated in the colorectal cancer cell line HCT 116. Pradimicin-IRD presented antitumor effects occurring after at least 6 h of exposure. Pradimicin-IRD induced statistically significant DNA damage (γH2AX and p21), apoptosis (PARP1 and caspase 3 cleavage) and cell cycle arrest (reduced Rb phosphorylation, cyclin A and cyclin B expression) markers. In accordance with these results, pradimicin-IRD increased cell populations in the subG1 and G0/G1 phases of the cell cycle. Additionally, mass spectrometry analysis indicated that pradimicin-IRD interacted with the DNA double strand. In summary, pradimicin-IRD exhibits multiple antineoplastic activities-including DNA damage, cell cycle arrest, reduction of clonal growth and apoptosis-in the HCT 116 cell line. Furthermore, pradimicin-IRD displays a TP53-independent regulation of p21 expression in HCT 116 TP53-/-, HT-29, SW480, and Caco-2 cells. This exploratory study identified novel targets for pradimicin-IRD and provided insights for its potential anticancer activity as a DNA-damaging agent.
Insights
Pradimicin-IRD, a novel antibiotic, shows significant anticancer activity by inducing DNA damage, apoptosis, and cell cycle arrest in colon cancer cells. This compound offers a promising new therapeutic option, particularly for drug-resistant cancers.
Area of Science:
- Pharmacology and Toxicology
- Molecular Biology
- Oncology
Background:
- DNA-damaging agents are crucial in cancer therapy but face limitations due to toxicity and drug resistance.
- Novel therapeutic agents are essential to overcome these challenges and improve patient outcomes.
- Pradimicin-IRD, a polycyclic antibiotic from Amycolatopsis sp., previously demonstrated antimicrobial and potential anticancer properties.
Purpose of the Study:
- To further investigate the cytotoxic activity of pradimicin-IRD against colon cancer cells.
- To elucidate the cellular and molecular mechanisms underlying pradimicin-IRD's antitumor effects.
- To assess the potential of pradimicin-IRD as a novel DNA-damaging anticancer agent.
Main Methods:
- Cytotoxic activity of pradimicin-IRD was evaluated in five colon cancer cell lines and non-tumor fibroblasts.
- Cellular and molecular mechanisms were studied in HCT 116 colorectal cancer cells, including DNA damage, apoptosis, and cell cycle markers.
- Mass spectrometry was employed to analyze pradimicin-IRD's interaction with DNA.
Main Results:
- Pradimicin-IRD exhibited significant cytotoxic effects against all tested colon cancer cells (IC50 in micromolar range) with greater selectivity than against normal fibroblasts.
- The compound induced DNA damage (γH2AX, p21), apoptosis (PARP1, caspase 3 cleavage), and cell cycle arrest (reduced Rb phosphorylation, altered cyclin expression).
- Pradimicin-IRD demonstrated TP53-independent regulation of p21 expression and direct interaction with DNA.
Conclusions:
- Pradimicin-IRD possesses multiple antineoplastic activities, including DNA damage, apoptosis induction, and cell cycle arrest, making it a promising anticancer agent.
- The drug's efficacy is observed across various colon cancer cell lines, including those with common TP53 and KRAS mutations.
- Pradimicin-IRD represents a potential novel therapeutic strategy, particularly as a DNA-damaging agent for cancer treatment.
Related Concept Videos
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
The Colonization of Land
Induced Pluripotent Stem Cells
Overview of DNA Repair
Chemically...
Mechanisms of Retrovirus-induced Cancers

